October 11, 2018
Tumor Homograft Model Generation: Dissociated Tumor Cells vs Tumor Fragments
Novel murine immunocompetent models are needed to overcome issues with commonly used syngeneic tumor models and genetically-engineered animal models. Today we review tumor homograft models and the alternative ways they can be created.
LEARN MORE
October 9, 2018
Why PDX Are Needed for Metastatic Breast Cancer Research
Metastatic breast cancer is currently incurable, though preclinical research is ongoing. Generating new therapies for ...
LEARN MORE
October 3, 2018
Oncolytic Viruses in Cancer Therapy
While viral therapy has existed conceptually for some time, it has only recently gained traction as a promising ...
LEARN MORE
September 13, 2018
CAR-T Cell Therapy for Solid Tumors
CAR-T cell therapies are currently only approved for blood cancers, but new preclinical research shows promise in using ...
LEARN MORE
September 4, 2018
Prostate Cancer Patient-Derived Xenograft (PDX) Models
Clinically-relevant prostate cancer patient-derived xenograft (PDX) models are notoriously hard to generate. Here we ...
LEARN MORE
August 31, 2018
Why Are Prostate Cancer Preclinical Models Hard to Develop?
Prostate cancer is a particularly difficult cancer type to model for preclinical research. Why are prostate cancer ...
LEARN MORE
August 17, 2018
Facilitating Drug Discovery with 3D In Vitro Oncology Models
Around 95% of new anticancer drugs eventually fail in clinical trials, despite promising results when tested on 2D in vitro preclinical models. New models that better mimic tumor biology in vivo can facilitate more efficient and translatable drug discovery research.
LEARN MORE
July 26, 2018
IDO to I DON’T – IDO1 Inhibitor Development News
As targeted immuno-oncology agents make impressive strides in cancer treatment, researchers are looking for agents that ...
LEARN MORE
July 5, 2018
Personalized Cancer Immunotherapy
Precision medicine and immunotherapy are currently two of the hottest areas of cancer research. How can immuno-oncology ...
LEARN MORE
July 3, 2018
Custom Murine Tumor Homografts for Efficacy Assessment
Murine tumor homografts provide an immunotherapeutic efficacy testing platform with the strengths of GEMM paired with ...
LEARN MORE
June 28, 2018
Assessing Combination Therapies in Syngeneic Tumor Models
Combination immunotherapy could enhance the clinical benefits of monotherapies and overcome patient lack of response to these novel agents. This means assessing a wide range of potential combinations, and syngeneic tumor models provide an ideal evaluation platform.
LEARN MORE
June 26, 2018
Why to Use Isotype Control Antibodies
Good experimental design is key to accurate and precise drug development. Isotype control antibodies, designed and ...
LEARN MORE
June 21, 2018
Immunocompetent Murine Models for Immunotherapy Assessment
Immunocompetent models are necessary for the preclinical assessment of novel immunotherapies, but multiple murine model ...
LEARN MORE
June 12, 2018
Leveraging PDX Models for In Vitro and Ex Vivo Assays
Patient-derived xenografts (PDX) are the most predictive and translational xenograft models available for preclinical ...
LEARN MORE
June 5, 2018
PDX and Personalized Medicine
We discussed patient-derived xenografts (PDX) previously, from how to establish the models to when to add them to ...
LEARN MORE
